164 related articles for article (PubMed ID: 30380599)
1. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Rustum YM; Chintala S; Durrani FA; Bhattacharya A
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
[TBL] [Abstract][Full Text] [Related]
2. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
3. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism.
Du W; Zhang L; Brett-Morris A; Aguila B; Kerner J; Hoppel CL; Puchowicz M; Serra D; Herrero L; Rini BI; Campbell S; Welford SM
Nat Commun; 2017 Nov; 8(1):1769. PubMed ID: 29176561
[TBL] [Abstract][Full Text] [Related]
4. A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma.
Brugarolas J; Obara G; Beckermann KE; Rini B; Lam ET; Hamilton J; Schluep T; Yi M; Wong S; Mao ZL; Gamelin E; Tannir NM
Clin Cancer Res; 2024 Jun; 30(11):2402-2411. PubMed ID: 38652038
[TBL] [Abstract][Full Text] [Related]
5. TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy.
Huang Y; Xiong Z; Wang J; Gao Y; Cao Q; Wang D; Shi J; Chen Z; Yang X
J Transl Med; 2024 Feb; 22(1):212. PubMed ID: 38419050
[TBL] [Abstract][Full Text] [Related]
6. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Choueiri TK; Powles T; Voss MH; Plimack ER; Gurney H; Song Y; Perini RF; Rodriguez-Lopez K; Rini BI
Future Oncol; 2023 Dec; 19(40):2631-2640. PubMed ID: 37882432
[TBL] [Abstract][Full Text] [Related]
7. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Jonasch E; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Dror Michaelson M; Appleman LJ; Roy A; Perini RF; Liu Y; Choueiri TK
Eur J Cancer; 2024 Jan; 196():113434. PubMed ID: 38008031
[TBL] [Abstract][Full Text] [Related]
8. Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.
Zakharia Y; Bhattacharya A; Rustum YM
Oncotarget; 2018 Feb; 9(12):10765-10783. PubMed ID: 29535842
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of UBB potentiates SP1/VEGFA-dependent angiogenesis in clear cell renal cell carcinoma.
Wang J; Zhao E; Geng B; Zhang W; Li Z; Liu Q; Liu W; Zhang W; Hou W; Zhang N; Liu Z; You B; Wu P; Li X
Oncogene; 2024 May; 43(18):1386-1396. PubMed ID: 38467852
[TBL] [Abstract][Full Text] [Related]
10. HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
Ma Y; Joyce A; Brandenburg O; Saatchi F; Stevens C; Toffessi Tcheuyap V; Christie A; Do QN; Fatunde O; Macchiaroli A; Wong SC; Woolford L; Yousuf Q; Miyata J; Carrillo D; Onabolu O; McKenzie T; Mishra A; Hardy T; He W; Li D; Ivanishev A; Zhang Q; Pedrosa I; Kapur P; Schluep T; Kanner SB; Hamilton J; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(24):5405-5418. PubMed ID: 36190432
[TBL] [Abstract][Full Text] [Related]
11. Chemokines as therapeutic targets in renal cell carcinoma.
Reckamp KL; Strieter RM; Figlin RA
Expert Rev Anticancer Ther; 2008 Jun; 8(6):887-93. PubMed ID: 18533798
[TBL] [Abstract][Full Text] [Related]
12. Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma.
Goodstein T; Yang Y; Runcie K; Srinivasan R; Singer EA
Curr Opin Oncol; 2023 May; 35(3):206-217. PubMed ID: 37226958
[TBL] [Abstract][Full Text] [Related]
13. Targeting apoptosis in clear cell renal cell carcinoma.
Kowalewski A; Borowczak J; Maniewski M; Gostomczyk K; Grzanka D; Szylberg Ł
Biomed Pharmacother; 2024 Jun; 175():116805. PubMed ID: 38781868
[TBL] [Abstract][Full Text] [Related]
14. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
[TBL] [Abstract][Full Text] [Related]
15. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.
Rustum YM; Reis R; Rustum TM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674417
[TBL] [Abstract][Full Text] [Related]
16. Seleno-Metabolites and Their Precursors: A New Dawn for Several Illnesses?
Morán-Serradilla C; Angulo-Elizari E; Henriquez-Figuereo A; Sanmartín C; Sharma AK; Plano D
Metabolites; 2022 Sep; 12(9):. PubMed ID: 36144278
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets.
Swearson S; Rataan AO; Eliason S; Amendt BA; Zakharia Y; Salem AK; Ho T; Rustum YM
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628416
[TBL] [Abstract][Full Text] [Related]
18. Potential Role of Selenium in the Treatment of Cancer and Viral Infections.
Rataan AO; Geary SM; Zakharia Y; Rustum YM; Salem AK
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216330
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α Induces HECTD2 Up-Regulation and Aggravates the Malignant Progression of Renal Cell Cancer
Lv D; Shen T; Yao J; Yang Q; Xiang Y; Ma Z
Front Cell Dev Biol; 2021; 9():775642. PubMed ID: 35004677
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma.
Giubellino A; Ricketts CJ; Moreno V; Linehan WM; Merino MJ
J Cancer; 2021; 12(18):5375-5384. PubMed ID: 34405000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
